Showing 1,659 news articles about Hepatitis & HIV

Filters Content type: Editors' picks Topic: Hepatitis & HIV

Hepatitis A, B and C are viral infections that can damage the liver and cause serious illnesses. Co-infection with HIV and hepatitis B or C is quite common. Safe and effective treatments are available.

New & experimental hepatitis C treatment

Eight Weeks of Treatment with AbbVie's Investigational, Pan-Genotypic, Ribavirin-free Regimen of Glecaprevir/Pibrentasvir (G/P) for Chronic Hepatitis C Achieved High SVR12 Rates in Genotype 1 Japanese Patients

Editor's pick
AbbVIe press release
9 January 2017
Access to healthcare

Access to highly effective hepatitis C treatment in Portugal: A Community Perspective

Editor's pick
EATG
19 December 2016
Pharmaceutical industry

Gilead’s Patent Loss to Merck Started With a Broken Friendship

Editor's pick
Bloomberg
19 December 2016
Access to healthcare

Hepatitis C patients 'go abroad for drugs'

Editor's pick
BBC Radio 4 (audio)
19 December 2016
Pharmaceutical industry

Merck wins $2.54 billion in hepatitis C drug trial against Gilead

Editor's pick
Reuters
16 December 2016
Hepatitis C symptoms & diagnosis

First WHO prequalified hepatitis C rapid test opens the door to expanded treatment

Editor's pick
World Health Organization
5 December 2016
Hepatitis C treatment

Hepatitis C drugs Australia's most expensive, cost taxpayers $1 billion in four months

Editor's pick
ABC Online
5 December 2016
Access to healthcare

New WHO report shows strategic purchasing of medicines can improve access in the European Region

Editor's pick
World Health Organization
2 December 2016
Hepatitis C transmission & prevention

Hepatitis C Sheds Enough in the Rectum to Transmit Through Anal Sex

Editor's pick
Poz
30 November 2016
Hepatitis C treatment

DAA treatment restricted for Canadian hepatitis C patients

Editor's pick
Medical Economics
29 November 2016
Access to healthcare

Where hepatitis C rates are seven times the US average — and a cure is kept out of reach

Editor's pick
STAT
14 November 2016
Hepatitis B

U.S. Food and Drug Administration Approves Gilead’s Vemlidy® (Tenofovir Alafenamide) for the Treatment of Chronic Hepatitis B Virus Infection

Editor's pick
Gilead press release
11 November 2016
Access to healthcare

These researchers think they have a solution to the global crisis in drug prices

Editor's pick
Washington Post
8 November 2016
Access to healthcare

Buyers clubs for cheaper drugs help fight hepatitis and HIV

Editor's pick
Reuters
7 November 2016
Hepatitis C treatment

The Cost Of A Cure: Revisiting Medicare Part D And Hepatitis C Drugs

Editor's pick
Health Affairs (blog)
4 November 2016
Pharmaceutical industry

Gilead sales of Hepatitis C drugs slump

Editor's pick
MarketWatch
2 November 2016
Access to healthcare

Over 1 million treated with highly effective hepatitis C medicines

Editor's pick
World Health Organization
27 October 2016
Hepatitis C treatment

A promising Hep C program seems to be working — and it could be a model for other countries

Editor's pick
Business Insider
24 October 2016
Hepatitis C treatment

Eliminating hepatitis C as a major public health threat needs a two-pronged attack

Editor's pick
Public Health England
18 October 2016
Drug policy & policing

Decriminalization is a public health strategy

Editor's pick
Treatment Action Group
18 October 2016
Hepatitis C treatment

Punjab hepatitis control programme on verge of collapse

Editor's pick
Daily Times
18 October 2016
Hepatitis C treatment

People infected by hepatitis C in Canada have limited access to direct-acting antivirals

Editor's pick
CRCHUM Montreal
17 October 2016
Pharmaceutical industry

European regulator amends some Gilead hep C patent claims

Editor's pick
STAT
6 October 2016
Hepatitis C treatment

HCV Drugs May Reactivate HBV, FDA Warns

Editor's pick
Medscape (free registration required)
6 October 2016